#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

CHICA­GO — The Dai­ichi Sankyo sto­ry made waves Sun­day at the an­nu­al AS­CO meet­ing in Chica­go, as En­her­tu po­ten­tial­ly dis­rupt­ed the breast can­cer land­scape by adding HER2-low to the dic­tio­nary, and Zymeworks wants to fol­low in their foot­steps.

Specif­i­cal­ly, the strug­gling biotech — which re­cent­ly hired a new CEO, re­placed most of the C-suite, laid off staff and re­ject­ed a hos­tile takeover bid — wants a glob­al part­ner just like Dai­ichi got in its $6 bil­lion 2019 deal with As­traZeneca to help turn En­her­tu in­to what it is to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER